Details of the Drug

General Information of Drug (ID: DM7UF9M)

Drug Name

Omiganan

Synonyms

CLS-001; MBI-594AN; MX-594AN; Omiganan (topical, acne/rosacea); Omiganan (topical, acne/rosacea), Biowest Therapeutics/Cutanea; Omiganan (topical, acne/rosacea), MIGENIX/Cutanea

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Phase 3	[1]
Rosacea	ED90.0	Phase 3	[2]
Acne vulgaris	ED80	Phase 2	[2]
Atopic dermatitis	EA80	Phase 2	[2]
External genital and perianal wart	1A95	Phase 2	[2]
Vulvar intraepithelial neoplasia	2E67.10	Phase 2	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C90H127N27O12
Canonical SMILES: CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC3C(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N8CCCC8C(=O)NC(CC9=CNC1=CC=CC=C19)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)N)N
InChI: 1S/C90H127N27O12/c1-5-51(4)75(92)85(127)113-68(41-50(2)3)80(122)109-67(32-18-38-102-90(98)99)79(121)114-71(44-54-48-105-62-27-12-8-23-58(54)62)86(128)116-39-19-34-74(116)84(126)112-70(43-53-47-104-61-26-11-7-22-57(53)61)82(124)115-72(45-55-49-106-63-28-13-9-24-59(55)63)87(129)117-40-20-33-73(117)83(125)111-69(42-52-46-103-60-25-10-6-21-56(52)60)81(123)110-66(31-17-37-101-89(96)97)78(120)108-65(30-16-36-100-88(94)95)77(119)107-64(76(93)118)29-14-15-35-91/h6-13,21-28,46-51,64-75,103-106H,5,14-20,29-45,91-92H2,1-4H3,(H2,93,118)(H,107,119)(H,108,120)(H,109,122)(H,110,123)(H,111,125)(H,112,126)(H,113,127)(H,114,121)(H,115,124)(H4,94,95,100)(H4,96,97,101)(H4,98,99,102)/t51-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-/m0/s1
InChIKey: MVPAMLBUDIFYGK-BHDRXCTLSA-N

Cross-matching ID

PubChem CID: 16131445
CAS Number: 204248-78-2
TTD ID: D0JW7D

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT00231153) Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)